Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy

Background/Aim: We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC). Patients and Methods: We retrospectively evaluated 26 patients with RR-DTC who underwent sorafenib therapy between July 2014 and December 2020. The systemic immunity markers were calculated from blood cell counts. Results: The median overall survival (OS) was 2,002 days, and the clinical benefit rate was 80.8%. The high lymphocyte-to-monocyte ratio (LMR) group had significantly longer OS than the low LMR group (hazard ratio=0.21; 95% confidence interval=005-0.88; log-rank p=0.019). Adverse events observed in this study were acceptable, and no new safety signals associated with sorafenib were found. Conclusion: Sorafenib therapy is efficacious and safe for Japanese patients with RR-DTC, and baseline LMR may be useful as a sorafenib therapy prognostic marker.

Download Full-text

Prognostic value of N0 classification in differentiated thyroid cancer

Endocrine Abstracts ◽

10.1530/endoabs.56.gp243 ◽

2018 ◽

Author(s):

Bernardo Marques ◽

Raquel Martins ◽

Joana Couto ◽

Jacinta Santos ◽

Teresa Martins ◽

...

Keyword(s):

Thyroid Cancer ◽

Prognostic Value ◽

Differentiated Thyroid Cancer

Download Full-text

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial

Head and neck tumors (HNT) ◽

10.17650/2222-1468-2018-8-2-39-52 ◽

2018 ◽

Vol 8 (2) ◽

pp. 39-52

Author(s):

M. S. Brose ◽

F. P. Worden ◽

K. L. Newbold ◽

M. Guo ◽

A. Hurria

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Select Trial ◽

Effect Of Age

Download Full-text

PROGNOSTIC VALUE OF SERUM THYROGLOBULIN MEASURED AT 48 HOURS VERSUS 72 HOURS AFTER SECOND DOSE OF RECOMBINANT HUMAN THYROTROPIN IN SURVEILLANCE OF WELL-DIFFERENTIATED THYROID CANCER

Endocrine Practice ◽

10.1016/j.eprac.2020.09.002 ◽

2020 ◽

Author(s):

Shirin Haddady ◽

Emma Pinjic ◽

Stephanie L. Lee

Keyword(s):

Thyroid Cancer ◽

Prognostic Value ◽

Differentiated Thyroid Cancer ◽

Serum Thyroglobulin ◽

Well Differentiated ◽

Recombinant Human Thyrotropin

Download Full-text

BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma

International Journal of Endocrinology ◽

10.1155/2019/3081497 ◽

2019 ◽

Vol 2019 ◽

pp. 1-7

Author(s):

Andrea Repaci ◽

Valentina Vicennati ◽

Alexandro Paccapelo ◽

Ottavio Cavicchi ◽

Nicola Salituro ◽

...

Keyword(s):

Thyroid Cancer ◽

Risk Stratification ◽

Prognostic Value ◽

Differentiated Thyroid Cancer ◽

Risk Classification ◽

Classification Systems ◽

Braf V600e ◽

American Thyroid Association ◽

Persistent Disease ◽

Ablation Time

Background. Stimulated thyroglobulin levels measured at the time of remnant ablation (A-hTg) and BRAFV600E mutation had shown prognostic value in predicting persistent disease in differentiated thyroid cancer (DTC). The aim of this study was to evaluate the prognostic role of A-hTg combined with the BRAFV600E status in association with the revised American Thyroid Association (ATA) risk stratification. Material and Methods. 620 patients treated for a DTC were included in this study with a median follow-up duration of 6.1 years. All patients underwent total thyroidectomy followed by radioiodine ablation. Patients with positive anti-thyroglobulin antibodies were excluded. The predictive value of A-hTg was calculated by receiver operating characteristic curve (ROC curve) analysis. The Cox proportional hazard regression model, including the BRAF status, A-hTg, and ATA classification system, was assessed to evaluate the existing persistent disease risk. Results. Taken together, the BRAF status and A-hTg levels improve the ATA risk classification in all categories. In particular, in the low-risk ATA classification, only the combination of BRAFV600E+A-hTg>8.9ng/ml was associated with persistent disease (P=0.001, HR 60.2, CI 95% 5.28-687). In the intermediate-risk ATA classification, BRAFWT+A-hTg>8.9ng/ml was associated with persistent disease (P=0.029, HR 2.71, CI 95% 1.106-6.670) and BRAFV600E+A-hTg>8.9ng/ml was also associated with persistent disease (P<0.001, HR 5.001, CI 95% 2.318-10.790). In the high-risk ATA classification, both BRAFV600E+A-hTg<8.9ng/ml and BRAFV600E+A-hTg>8.9 ng/ml were associated with persistent disease (P=0.042, HR 5.963, CI 95% 1.069-33.255 and P=0.002, HR 11.564, CI 95% 2.543-52.576, respectively). Conclusions. The BRAF status and stimulated thyroglobulin levels at ablation time improve the ATA risk stratification of differentiated thyroid cancer; therefore, even A-hTg could be included in risk classification factors.

Download Full-text